Merck & Company, Inc. vs TransMedics Group, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
8.8
Very Bullish
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
TMDX
Earnings growing 1188% year-over-year on 32% revenue growth.
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $156.00 (+56.0%)
10 analysts
Fundamentals
MRK
TMDX
31.5×
Trailing P/E
20.5×
11.5×
Forward P/E
27.2×
13.6%
Profit Margin
31.4%
76.6%
Gross Margin
59.9%
—
ROE
54.2%
4.9%
Revenue Growth
32.2%
—
Earnings Growth
1188.1%
0.28
Beta
2.08
—
Price / Book
—
$277.0B
Market Cap
$3.5B
$73 – $125
52-Week Range
$90 – $156
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →